Mega Lifesciences Past Earnings Performance
Past criteria checks 3/6
Mega Lifesciences has been growing earnings at an average annual rate of 15.1%, while the Pharmaceuticals industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 9.4% per year. Mega Lifesciences's return on equity is 21.4%, and it has net margins of 12.7%.
Key information
15.1%
Earnings growth rate
15.0%
EPS growth rate
Pharmaceuticals Industry Growth | 12.4% |
Revenue growth rate | 9.4% |
Return on equity | 21.4% |
Net Margin | 12.7% |
Next Earnings Update | 13 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Mega Lifesciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 15,716 | 1,993 | 4,191 | 0 |
30 Sep 23 | 15,442 | 1,919 | 4,278 | 0 |
30 Jun 23 | 15,693 | 2,042 | 4,352 | 0 |
31 Mar 23 | 15,634 | 2,081 | 4,398 | 0 |
31 Dec 22 | 15,727 | 2,242 | 4,359 | 0 |
30 Sep 22 | 15,116 | 2,338 | 4,068 | 0 |
30 Jun 22 | 15,061 | 2,292 | 4,054 | 0 |
31 Mar 22 | 14,724 | 2,227 | 3,924 | 0 |
31 Dec 21 | 14,172 | 1,947 | 3,769 | 0 |
30 Sep 21 | 14,395 | 1,878 | 3,767 | 0 |
30 Jun 21 | 13,775 | 1,607 | 3,538 | 0 |
31 Mar 21 | 12,809 | 1,406 | 3,331 | 0 |
31 Dec 20 | 12,613 | 1,393 | 3,288 | 0 |
30 Sep 20 | 12,168 | 1,348 | 3,169 | 0 |
30 Jun 20 | 11,642 | 1,288 | 3,137 | 0 |
31 Mar 20 | 11,655 | 1,205 | 3,195 | 0 |
31 Dec 19 | 11,164 | 1,139 | 3,176 | 0 |
30 Sep 19 | 10,950 | 1,163 | 3,198 | 0 |
30 Jun 19 | 10,712 | 1,136 | 3,153 | 0 |
31 Mar 19 | 10,569 | 1,203 | 3,113 | 0 |
31 Dec 18 | 10,284 | 1,206 | 3,052 | 0 |
30 Sep 18 | 10,147 | 1,183 | 3,041 | 0 |
30 Jun 18 | 9,937 | 1,175 | 3,010 | 0 |
31 Mar 18 | 9,829 | 1,178 | 2,988 | 0 |
31 Dec 17 | 9,624 | 1,113 | 2,965 | 0 |
30 Sep 17 | 9,514 | 1,023 | 2,928 | 0 |
30 Jun 17 | 9,282 | 945 | 2,869 | 0 |
31 Mar 17 | 8,968 | 873 | 2,766 | 0 |
31 Dec 16 | 8,828 | 795 | 2,674 | 0 |
30 Sep 16 | 8,514 | 771 | 2,603 | 0 |
30 Jun 16 | 8,226 | 756 | 2,658 | 0 |
31 Mar 16 | 8,115 | 703 | 2,714 | 0 |
31 Dec 15 | 7,966 | 696 | 2,718 | 0 |
30 Sep 15 | 7,775 | 675 | 2,668 | 0 |
30 Jun 15 | 7,862 | 634 | 2,580 | 0 |
31 Mar 15 | 7,851 | 598 | 2,486 | 0 |
31 Dec 14 | 7,749 | 548 | 2,471 | 0 |
30 Sep 14 | 7,620 | 474 | 2,454 | 0 |
30 Jun 14 | 7,422 | 516 | 2,362 | 0 |
31 Mar 14 | 7,226 | 567 | 2,304 | 0 |
31 Dec 13 | 7,055 | 624 | 2,236 | 0 |
30 Sep 13 | 6,812 | 593 | 2,190 | 0 |
30 Jun 13 | 6,592 | 568 | 2,166 | 0 |
Quality Earnings: MEGA has high quality earnings.
Growing Profit Margin: MEGA's current net profit margins (12.7%) are lower than last year (14.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MEGA's earnings have grown by 15.1% per year over the past 5 years.
Accelerating Growth: MEGA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MEGA had negative earnings growth (-11.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (5.7%).
Return on Equity
High ROE: MEGA's Return on Equity (21.4%) is considered high.